Search Within

Center for Pancreatic Cancer Research

Formats
  1. Journal Article (5066)
  2. Meeting Abstract (2484)
  3. Book Section (225)
  4. Review (221)
  5. Editorial (135)
  6. Conference Paper (75)
  7. Correspondence (48)
  8. Research Letter (43)
  9. Miscellaneous (41)
  10. Guidelines (38)
  11. Book Whole (20)
Groups
  1. Department of Medicine (3948)
  2. Solid Tumor Oncology Division (3245)
  3. Surgery (3172)
  4. GSK Faculty (2917)
  5. Epidemiology and Biostatistics (2529)
  6. Gastrointestinal Oncology Service (2300)

More Groups

People
  1. Mithat Gonen (1036)
  2. William Jarnagin (913)
  3. Eileen O'Reilly (796)
  4. Michael D'Angelica (789)
  5. T Peter Kingham (622)
  6. David Kelsen (538)

More People

Years
  1. 2025 (297)
  2. 2024 (497)
  3. 2023 (523)
  4. 2022 (602)
  5. 2021 (555)
  6. 2020 (562)

More Years

Publications
  1. Journal of Clinical Oncology (927)
  2. Annals of Surgical Oncology (397)
  3. Cancer Research (226)
  4. International Journal of Radiation Oncology, Biology, Physics (219)
  5. Laboratory Investigation (209)
  6. Modern Pathology (191)

More Publications

Publishers
  1. American Society of Clinical Oncology (1003)
  2. Springer (843)
  3. Elsevier Inc. (757)
  4. Nature Publishing Group (633)
  5. American Association for Cancer Research (551)
  6. Elsevier Science, Inc. (510)

More Publishers

Results (8396)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The association of age with acute toxicities in NRG oncology combined modality lower GI cancer trials
    Meeting Abstract

    VanderWalde, N. A.; Moughan, J.; Lichtman, S. M.; Jagsi, R.; Ballo, M. T.; Vanderwalde, A. M.; Mohiuddin, M.; Meropol, N. J.; Kachnic, L. A.; Garofalo, M. C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone)
    Meeting Abstract

    Mulvey, C.; Raj, N. P.; Chan, J. A.; Aggarwal, R. R.; Cinar, P.; Hope, T. A.; Kolli, K.; Zhang, L.; Calabrese, S.; Grabowsky, J. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Pilot study of plasma KRAS as a prognostic biomarker in localized pancreas ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Krantz, B. A.; Gedvilaite, E.; Chou, J. F.; Capanu, M.; You, D.; Yu, K. H.; Varghese, A. M.; Iacobuzio-Donahue, C. A.; Kelsen, D. P.; Tsui, D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • KRAS and TP53 status as a predictor of survival in patients with resected pancreatic ductal adenocarcinoma
    Meeting Abstract

    McIntyre, C. A.; Lawrence, S. A.; Wong, W.; Chou, J. F.; Capanu, M.; Berger, M. F.; Allen, P.; O'Reilly, E. M.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase II study of ADI-PEG 20 and FOLFOX6 in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Harding, J. J.; Qin, S.; Yang, T. S.; Yen, C. J.; Chao, Y.; Wang, T. E.; Do, R. K. G.; El Dika, I. H.; Uhlitskykh, K.; Millang, B. M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance)
    Meeting Abstract

    Hatch, A. J.; Ou, F. S.; Zemla, T.; Starr, M. D.; Brady, J. C.; Liu, Y.; Innocenti, F.; Meyerhardt, J. A.; O'Reilly, E. M.; Lenz, H. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)
    Meeting Abstract

    Janjigian, Y. Y.; Chou, J. F.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; Chong, C. R.; Gerdes, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinicopathological features for whom adjuvant treatment may be avoided
    Meeting Abstract

    Galon, J.; Hermitte, F.; Mlecnik, B.; Marliot, F.; Bifulco, C. B.; Lugli, A.; Nagtegaal, I. D.; Hartmann, A.; Van den Eynde, M.; Roehrl, M. H. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Systemic chemo (CTX) plus surgery and intraperitoneal (IP) CTX for patients (pts) with gastric cancer (GC) and peritoneal carcinomatosis (PC)
    Meeting Abstract

    Greally, M.; Strong, V. E.; Yoon, S. S.; Chou, J. F.; Capanu, M.; Kelsen, D. P.; Janjigian, Y. Y.; Ilson, D. H.; Ku, G. Y.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase I/Ib study of crenolanib with ramucirumab (RAM)/paclitaxel (PTX) as second -line therapy (2L tx) for advanced esophagogastric adenocarcinoma (EGA)
    Meeting Abstract

    Greally, M.; Jha, S.; Yoon, S. S.; Li, J.; Desai, A. M.; Won, E.; Kelsen, D. P.; Ilson, D. H.; Janjigian, Y. Y.; Aljallad, K.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save